COVID-19 Clinical Trial
Official title:
ABO Blood Group Type Association With COVID-19 Severity - A Single Center Study
The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.
The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question. Early reports have indicated a significant relationship of ABO blood group types to the risk of infection with SARS-CoV-2. Specifically, the first systematic review and meta-analysis by Wu et al. in October 2020 cited that blood type A had increased risk for infection with SARS-CoV-2 and blood type O had decreased risk of infection. Another early meta-analysis by Zaidi et al. cited that blood type A had increased odds of infection, type O had decreased odds of infection, type AB had increased risk of disease severity, and type B had decreased risk of demise. As more multi-national data became available, as a result of global concerted efforts, larger studies produced data to further investigate this connection. Overall, the majority of studies reproduced similar data: type O had decreased risk of infection with SARS-CoV-2, while type A had increased risk of infection. One study in the United Kingdom failed to produce a relationship between blood types and COVID-19. As more data became available, several studies were able to study the association of blood group type with mortality and disease severity; however, the data regarding this is inconsistent. Gutierrez-Valencia et al. did not find an association with blood types and ICU admission or mechanical ventilation; however, they did note an increased risk of mortality in blood type A. Liu et al. and Pereira et al. demonstrated that there is also increased risk of mortality in blood type A. Jerico et al. noted a lower risk for ICU admission in blood type O. Goel et al. noted an increased risk of disease severity in blood type A. As evident, it seems that blood type A has increased risk of mortality and, likely, disease severity. In this study, we aim to evaluate association of blood types with mortality and disease severity at a county hospital in Southern California. We will review charts for patients infected with SARS-CoV-2 during a two-year time period, evaluating mortality, oxygen requirements, and patient historical factors. Through this study, we aim to gain a better understanding of how blood group types may affect patient outcomes in the setting of COVID-19. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|